Advanced or metastatic non-small cell lung cancer (NSCLC) harboring a RET gene fusion defines a molecularly distinct subgroup that warrants a targeted treatment strategy. Identifying this alteration at diagnosis is essential to selecting the appropriate first-line approach.
RET gene fusions occur in approximately 1–2% of patients with NSCLC and are more common in adenocarcinoma histology. Importantly, the presence of a RET gene fusion — regardless of fusion partner — is associated with responsiveness to oral RET-directed targeted kinase inhibitors.
First-line targeted therapy is recommended for patients with advanced or metastatic NSCLC and a confirmed RET gene fusion, with specific preferred oral agents established for this molecular subtype.
RET gene fusions occur in about 1% to 2% of patients with NSCLC and are more frequent in patients with adenocarcinoma histology.
The presence of a RET gene fusion is associated with responsiveness to oral RET TKIs regardless of fusion partner.
The Panel recommends pralsetinib or selpercatinib as preferred first-line therapy options for patients with advanced or metastatic NSCLC and RET gene fusion; both are appropriate for a PS of 0–4.
View source ↗